Xenon Pharmaceuticals Inc. (XENE) stock
XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
$38.78−0.48 (-1.22%)
Close on Nov 17, 2026Market cap $3.76BP/E –Yield –
Xenon Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Xenon Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $352.49M, up 39.5% year over year. For fiscal 2025 it was $300.94M, up 43.0% from the year before. Over ten years it grew 34.8% a year on average. The highest annual figure on record is $300.94M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $300.94M | +43.0% |
| FY2024 | Dec 31, 2024 | $210.39M | +25.6% |
| FY2023 | Dec 31, 2023 | $167.51M | +58.4% |
| FY2022 | Dec 31, 2022 | $105.77M | +40.2% |
| FY2021 | Dec 31, 2021 | $75.46M | +49.4% |
| FY2020 | Dec 31, 2020 | $50.52M | +30.1% |
| FY2019 | Dec 31, 2019 | $38.85M | +64.4% |
| FY2018 | Dec 31, 2018 | $23.63M | -7.6% |
| FY2017 | Dec 31, 2017 | $25.57M | +29.0% |
| FY2016 | Dec 31, 2016 | $19.83M | +30.9% |
| FY2015 | Dec 31, 2015 | $15.15M | +28.8% |
| FY2014 | Dec 31, 2014 | $11.77M | -4.3% |
| FY2013 | Dec 31, 2013 | $12.30M | +17.7% |
| FY2012 | Dec 31, 2012 | $10.46M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $99.22M | +32.3% |
| Q1 FY2026 | Mar 31, 2026 | $88.51M | +44.6% |
| Q4 FY2025 | Dec 31, 2025 | $87.70M | +47.5% |
| Q3 FY2025 | Sep 30, 2025 | $77.05M | +35.3% |
| Q2 FY2025 | Jun 30, 2025 | $74.99M | +50.9% |
| Q1 FY2025 | Mar 31, 2025 | $61.20M | +38.3% |
| Q4 FY2024 | Dec 31, 2024 | $59.47M | +44.8% |
| Q3 FY2024 | Sep 30, 2024 | $56.97M | +32.9% |
| Q2 FY2024 | Jun 30, 2024 | $49.70M | +12.9% |
| Q1 FY2024 | Mar 31, 2024 | $44.25M | +12.0% |
| Q4 FY2023 | Dec 31, 2023 | $41.08M | +17.9% |
| Q3 FY2023 | Sep 30, 2023 | $42.88M | +45.7% |
| Q2 FY2023 | Jun 30, 2023 | $44.04M | +98.9% |
| Q1 FY2023 | Mar 31, 2023 | $39.52M | +104.1% |
| Q4 FY2022 | Dec 31, 2022 | $34.83M | +59.1% |
| Q3 FY2022 | Sep 30, 2022 | $29.43M | +55.8% |
| Q2 FY2022 | Jun 30, 2022 | $22.15M | +20.5% |
| Q1 FY2022 | Mar 31, 2022 | $19.36M | +18.7% |
| Q4 FY2021 | Dec 31, 2021 | $21.89M | +46.2% |
| Q3 FY2021 | Sep 30, 2021 | $18.89M | +44.8% |
| Q2 FY2021 | Jun 30, 2021 | $18.38M | +71.4% |
| Q1 FY2021 | Mar 31, 2021 | $16.31M | +38.3% |
| Q4 FY2020 | Dec 31, 2020 | $14.97M | +27.4% |
| Q3 FY2020 | Sep 30, 2020 | $13.05M | +33.8% |
| Q2 FY2020 | Jun 30, 2020 | $10.72M | +30.7% |
| Q1 FY2020 | Mar 31, 2020 | $11.79M | +29.0% |
| Q4 FY2019 | Dec 31, 2019 | $11.75M | +83.6% |
| Q3 FY2019 | Sep 30, 2019 | $9.75M | +56.1% |
| Q2 FY2019 | Jun 30, 2019 | $8.21M | +51.5% |
| Q1 FY2019 | Mar 31, 2019 | $9.14M | +64.1% |
| Q4 FY2018 | Dec 31, 2018 | $6.40M | +0.1% |
| Q3 FY2018 | Sep 30, 2018 | $6.25M | -12.8% |
| Q2 FY2018 | Jun 30, 2018 | $5.42M | -11.3% |
| Q1 FY2018 | Mar 31, 2018 | $5.57M | -5.7% |
| Q4 FY2017 | Dec 31, 2017 | $6.40M | +45.5% |
| Q3 FY2017 | Sep 30, 2017 | $7.16M | +20.1% |
| Q2 FY2017 | Jun 30, 2017 | $6.11M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.90M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.40M | – |
| Q3 FY2016 | Sep 30, 2016 | $5.97M | – |
See a number that looks wrong?